SUMMARY Urinary glycosaminoglycan (GAG) excretion was measured in 24 patients with active rheumatoid arthritis (RA) before and after treatment with conventional second-line agents. Urinary GAG excretion was also measured in normal controls, patients with osteoarthritis (OA), and patients with acute myocardial infarction (MI). Total GAG excretion was increased in the RA group and fell after second-line therapy (p<001). More low than high molecular weight GAG was excreted in the active RA group, and this pattern was reversed after treatment. Excretion of total, high and low molecular weight GAG in the OA group did not differ significantly from controls. Total GAG excretion was increased in the MI group when compared with controls (p<002) and consisted mainly of high molecular weight GAG. The serial measurement of urinary GAG provides a further index of disease activity and may help to monitor response to treatment.
Previous workers have shown that urinarv excretion of sulphated glycosaminoglycans (GAG) is increased in connective tissue disorders such as progressive systemic sclerosis' and rheumatoid arthritis (RA). 2 The amount of high molecular weight GAG and low molecular weight GAG excreted varies in different disorders and with disease activity.3 4 To establish whether measurement of urinary GAG excretion and the relative amounts of high and low molecular weight GAG provide a useful additional index of inflammatory disease activity, patients with RA were studied before and after commencing second-line drug therapy with chloroquine, gold, or D-penicillamine. The results of GAG excretion in RA were compared with GAG excretion in patients with osteoarthritis (OA), in patients after acute myocardial infarction (MI), and in normal controls. The OA and MI groups were chosen to study the effects of non-inflammatory joint disease and acute nonarticular tissue damage respectively on GAG excretion.
Accepted for publication 29 Differences between urinary GAG excretion in the RA and other groups were analysed by the Mann-Whitney U test; p values of 0-05 or less were considered statistically significant. Two-tailed tests were applied to the analysis of GAG excretion in all groups. A one-tailed Wilcoxon's rank sum test was used for the analysis of changes in clinical assessment in the RA group.
Results
The results of urinary GAG excretion in the pretreatment RA group, OA, MI, and control groups are recorded in Table 2 and show that the mean total urinary GAG excretion was higher in the pretreatment RA group than in the controls, though this did not reach statistical significance. The crosssectional statistical analysis of total GAG was biased group.bmj.com on June 27, 2017 -Published by http://ard.bmj.com/ Downloaded from not in the duration of morning stiffness. Fig. 1 compares the change in ESR and total urinary GAG excretion in the RA groups pre-and post-treatment. In the seven patients in whom the ESR rose over the study period, the total urinary GAG excretion fell in all but one. In four of these six patients the remaining parameters (morning stiffness and global activity) suggested improvement. In only one patient did the urinary GAG rise while the other parameters fell, but this was one of the two patients with a low pretreatment GAG value.
There were no differences in GAG excretion between the OA and control groups. In the MI group total urinary GAG excretion was significantly higher than in controls (p<002) and appeared to be due to an excess of high molecular weight GAG when compared with controls (p<0-001). From the GAG:creatinine ratio measured on random samples on three successive days postinfarct it was concluded that the high levels were not artefactuaf apd neither were peak levels of urinary GAG being missed by collecting the study sample in the 24 hours postinfarction. By obtaining 24-hour urine samples from all subjects in the main study creatinine estimation was considered unnecessary. There was no difference 
Discussion
This study shows that there is an increase in total urinary GAG excretion in patients with active RA and in patients after myocardial infarction but no increase in GAG excretion in patients with osteoarthritis. In RA, total urinary GAG excretion falls after response of the disease to second-line drug therapy but appears uninfluenced by treatment with non-steroidal anti-inflammatory drugs. Urinary GAG is thought to be derived from high molecular weight proteoglycans which have probably been released from the parent molecule by proteolytic digestion in vivo. conventional assessment techniques. The poor correlation noted between the change in ESR and change in urinary GAG excretion before and after second-line drug therapy in our minds invalidates neither assessment but rather supports the concept that the two measure different facets of the disease process. There is a wide variation in GAG excretion in both normal and disease groups, with considerable overlap, so that a single GAG measurement is of limited value. Serial measurements in individual patients may, however, be a useful indicator of either increasing activity or of response to secondline therapy. 
